目的 探讨雷公藤甲素抗骨质疏松的作用及机制。 方法 建立大鼠老年性骨质疏松模型。40只22月龄雄性SD大鼠随机分为雷公藤甲素（每天15 μg/kg腹腔注射）治疗组和生理盐水对照组（每天15μg/kg腹腔注射），连续8周。采用显微CT分析胫骨近端骨松质的骨密度(BMD)和骨显微结构。WB检测成骨相关蛋白表达水平。TRACP-5b染色法测定破骨细胞数，同时检测骨吸收标志物表达水平。 结果 显微CT结果显示，雷公藤甲素治疗组大鼠骨密度、骨体积/总体积比值(Bv/Tv)、骨小梁厚度(Tb.Th)、骨小梁数目(Tb.N)、骨小梁间距(Tb.Sp)均显著高于对照组（P<0.05）。两组的成骨相关蛋白表达水平无明显差异，TRACP-5b染色显示雷公藤甲素减少了体内破骨细胞的数量（P<0.05），同时血液骨吸收标志物水平也明显降低（P<0.05）。 结论 雷公藤甲素通过抑制破骨细胞生成进而对老年性骨质疏松有保护作用。雷公藤甲素可能是治疗老年性骨质疏松症的一种可行方案。
Abstract
Objective To investigate the antiosteoporotic effect and mechanism of triptolide. Methods A rat model of senile osteoporosis was established. Forty 22-month-old male SD rats were randomly divided into a treatment group of triptolide (15 μg/kg per day intraperitoneally) and a control group of saline (15 μg/kg per day intraperitoneally) for 8 weeks treatment. Bone mineral density (BMD) and bone microstructure of the proximal tibial cancellous were analyzed by micro-CT. Western blot was used to detect the expression level of osteogenic-related proteins. The number of osteoclasts was measured by TRACP-5b staining, and the expression levels of bone resorption markers were also detected. Results Micro-CT results showed that BMD, bone volume/total volume ratio (Bv/Tv), bone trabecular thickness (Tb.Th), bone trabecular number (Tb.N), and bone trabecular spacing (Tb.Sp) in the rats treated with ryanodine were significantly higher than those in the control group (P<0.05). There was no significant difference in osteogenesis-related protein expression between the two groups, and TRACP staining result showed that triptolide reduced the number of osteoclasts in vivo (P<0.05), while blood bone resorption marker levels were also significantly lower (P<0.05). Conclusions Triptolide has a protective effect on age-related osteoporosis by inhibiting osteoclastogenesis. Which may be a feasible option for the treatment of senile osteoporosis.
关键词
雷公藤甲素； /
/
骨质疏松； /
/
成骨细胞； /
/
破骨细胞
Key words
Triptolide; /
/
Osteoporosis; /
/
Osteoblast; /
/
Osteoclast
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Rubin CD. Age-related osteoporosis[J]. Am J Med Sci, 1991,301(4):281-298. DOI: 10.1097/00000441-199104000-00012.
[2] Heaney RP. Age-related osteoporosis in Chinese women[J]. Am J Clin Nutr, 1999,69(6):1291-1292. DOI: 10.1093/ajcn.
[3] Maclaughlin EJ, Sleeper RB, McNatty D, et al. Management of age-related osteoporosis and prevention of associated fractures[J]. Ther Clin Risk Manag, 2006,2(3):281-295. DOI: 10.2147/tcrm.2006.2.3.281.
[4] 丁超. 老年性骨质疏松症相关问题研究进展[J]. 中国骨质疏松杂志, 2016,22(3):372-375. DOI：10.3969/j.issn.1006-7108.2016.03.025.
[5] Compston JE, McClung MR, Leslie WD. Osteoporosis[J]. Lancet, 2019,393(10169):364-376. DOI: 10.1016/S0140-6736(18)32112-3.
[6] Wang Y, Wang B, Yang X. The Study of Cellular Mechanism of Triptolide in the Treatment of Cancer, Bone Loss and Cardiovascular Disease and Triptolide's Toxicity[J]. Curr Stem Cell Res Ther, 2020,15(1):18-23. DOI: 10.2174/1574888X14666190301155810.
[7] Park B. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells[J]. Biochimie, 2014,105:129-136. DOI: 10.1016/j.biochi.2014.07.003.
[8] Cui J, Li X, Wang S, et al. Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway[J]. J Cell Mol Med, 2020,24(11):6149-6161. DOI: 10.1111/jcmm.15229.
[9] 彭坤. 骨质疏松性骨折治疗效果的改善：研究现状及策略分析[J]. 中国组织工程研究, 2022, 26(6):1027-1032. DOI: 10.12307/2022.189.
[10]张文静. 骨质疏松治疗的相关研究进展[J]. 中国老年保健医学, 2020,18(04):101-102. DOI: 10.3969/j.issn.1672-2671.2020.04.033.
[11]井莹莹, 王一力, 苏佳灿. 骨微环境对骨质疏松性骨折骨愈合的作用及其机制[J]. 中华创伤杂志, 2021, 37(8):683-687. DOI: 10.3760/cma.j.cn501098-20210331-00215.
[12]邓飞飞, 宋强, 张成涛, 等. 骨质疏松相关分子病因及治疗研究进展[J]. 中华实验外科杂志, 2021,38(6):1186-1188. DOI: 10.3760/cma.j.cn421213-20201023-01379.
[13]林若慧, 李生强, 陈娟, 等. 长链非编码RNA的中医药治疗骨质疏松症研究进展[J]. 中国骨质疏松杂志, 2021,27(9):1395-1399. DOI: 10.3969/j.issn.1006-7108.2021.09.029.
[14]Ogbechi J, Clanchy FI, Huang YS, et al. IDO activation, inflammation and musculoskeletal disease[J]. Exp Gerontol, 2020,131:110820. DOI: 10.1016/j.exger.2019.110820.
[15]Lacativa PG, Farias ML. Osteoporosis and inflammation[J]. Arq Bras Endocrinol Metabol, 2010,54(2):123-132. DOI: 10.1590/s0004-27302010000200007.
[16] Fang H, Zhang H, Wang Z, et al. Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture[J]. J Clin Lab Anal, 2020,34(1):e23016. DOI: 10.1002/jcla.23016.
[17] 李晶芳, 韩蕊, 殷宏庆, 等. 雷公藤治疗肾脏疾病及其毒副作用的研究进展[J]. 中国实验方剂学杂志, 网络首发时间：2021-05-20. DOI: 10.13422/j.cnki.syfjx.20211305.
[18] Kitzen JJ, de Jonge MJ, Lamers CH, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours[J]. Eur J Cancer, 2009,45(10):1764-1772. DOI: 10.1016/j.ejca.2009.01.026.
[19] Yuan Z, Zhang H, Hasnat M, et al. A new perspective of triptolide-associated hepatotoxicity: Liver hypersensitivity upon LPS stimulation[J]. Toxicology, 2019,414:45-56. DOI: 10.1016/j.tox.2019.01.005.
基金
广东省中医药局科研项目（20191005）；广州市科技计划项目（202102080222）
PDF(3017 KB)
京ICP备08002354号-3
